Sodium glucose cotransporter 2 inhibitors and glucagon-like peptidase-1 receptor agonist use for T2DM can decrease transaminase activity in patients with NAFLD [27,28,29,30]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.